MXPA03011012A - Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil) propanoico o acido 3-(4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico e insulina. - Google Patents

Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil) propanoico o acido 3-(4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico e insulina.

Info

Publication number
MXPA03011012A
MXPA03011012A MXPA03011012A MXPA03011012A MXPA03011012A MX PA03011012 A MXPA03011012 A MX PA03011012A MX PA03011012 A MXPA03011012 A MX PA03011012A MX PA03011012 A MXPA03011012 A MX PA03011012A MX PA03011012 A MXPA03011012 A MX PA03011012A
Authority
MX
Mexico
Prior art keywords
ethoxy
phenyl
propanoic acid
insulin
tert
Prior art date
Application number
MXPA03011012A
Other languages
English (en)
Inventor
Hman Peter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA03011012A publication Critical patent/MXPA03011012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinacion farmaceutica que comprende ya sea acido (S)-2-etoxi-3- [4- (2-{ 4-metansulfoniloxifenil}etoxi)fenil]propanoico o acido 3-{4-[2-(4-ter-butoxicarbonilaminofenil)etoxi]fenil}-(S)-2-etoxi propanoico, o una sal farmaceuticamente aceptable de los mismos y cualquier solvatos de los mismos e insulina.
MXPA03011012A 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil) propanoico o acido 3-(4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico e insulina. MXPA03011012A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101981A SE0101981D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
PCT/SE2002/001037 WO2002096453A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin

Publications (1)

Publication Number Publication Date
MXPA03011012A true MXPA03011012A (es) 2004-02-27

Family

ID=20284363

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011012A MXPA03011012A (es) 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil) propanoico o acido 3-(4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico e insulina.

Country Status (22)

Country Link
US (1) US20040147600A1 (es)
EP (1) EP1401485A1 (es)
JP (1) JP2004532873A (es)
KR (1) KR20040072027A (es)
CN (1) CN1535155A (es)
BR (1) BR0210129A (es)
CA (1) CA2448637A1 (es)
CO (1) CO5540383A2 (es)
CZ (1) CZ20033233A3 (es)
EE (1) EE200300577A (es)
HU (1) HUP0400964A3 (es)
IL (1) IL159034A0 (es)
IS (1) IS7056A (es)
MX (1) MXPA03011012A (es)
NO (1) NO20035236D0 (es)
NZ (1) NZ529812A (es)
PL (1) PL367704A1 (es)
RU (1) RU2003136156A (es)
SE (1) SE0101981D0 (es)
SK (1) SK14712003A3 (es)
WO (1) WO2002096453A1 (es)
ZA (1) ZA200309261B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60308390T2 (de) * 2003-11-28 2007-09-06 Merck Santé Behandlung von Hyperurikämie
AR052888A1 (es) * 2005-01-28 2007-04-11 Lilly Co Eli Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion
CN102036559A (zh) * 2008-05-19 2011-04-27 雀巢产品技术援助有限公司 降低动物脂质吸收的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
EP1145717B1 (en) * 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone

Also Published As

Publication number Publication date
NZ529812A (en) 2006-03-31
CO5540383A2 (es) 2005-07-29
IL159034A0 (en) 2004-05-12
HUP0400964A2 (hu) 2004-08-30
PL367704A1 (en) 2005-03-07
EE200300577A (et) 2004-02-16
SE0101981D0 (sv) 2001-06-01
EP1401485A1 (en) 2004-03-31
KR20040072027A (ko) 2004-08-16
BR0210129A (pt) 2004-06-08
NO20035236D0 (no) 2003-11-25
IS7056A (is) 2003-11-28
CZ20033233A3 (cs) 2004-12-15
HUP0400964A3 (en) 2007-11-28
US20040147600A1 (en) 2004-07-29
RU2003136156A (ru) 2005-05-20
ZA200309261B (en) 2005-02-28
CN1535155A (zh) 2004-10-06
CA2448637A1 (en) 2002-12-05
SK14712003A3 (sk) 2004-08-03
JP2004532873A (ja) 2004-10-28
WO2002096453A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
EE200200284A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe peenestatud vorm
BRPI0410922A (pt) processo para a formação de um composto, e, composto
AU3957800A (en) Crystalline r- guanidines, arginine or (l) -arginine (2(s)) -2- ethoxy -3-(4- (2-(10(h) -phenoxazin -10-yl)ethoxy}phenyl)propanoate
IL190294A0 (en) Herbicidal compositions based on 3-phenyluracils and n-[[4-[(cyclopropylamino)-carbonyl]phenyl]sulfonyl]-2-methoxybenzamide
TR200003543T2 (tr) Yeni 3-aril-2-hidroksipropiyonik asit türevi III.
RS51497B (sr) w-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
PT1663236E (pt) Combinação compreendendo n-(3-metoxi-5-metilpirazin-2-il)-2-(4- [1,3,4-oxadiazol-2-il]fenil)piridina-3-sulfonamida e um bifosfonato
MXPA03011012A (es) Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil) propanoico o acido 3-(4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico e insulina.
MXPA03011005A (es) Una combinacion farmaceutica que comprende ya sea acido (s)-2- etoxi-3[4 (2-{4- metansulfonil oxifenil} etoxi)fenil] propanoico o acido 3-(4 -[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)- 2-etoxi propanoico y un faramco biguanida.
IL172633A0 (en) Amine salts of (-)-2-{[2-(4-hydroxyphenyl) ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}
MXPA03011010A (es) Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoxi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil] propanoico o acido 3-{4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico y una sulfonilurea.
IS8234A (is) Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræði
CO5590908A2 (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa
AU2034601A (en) Crystalline form of 3-(4-(2-(4-tert-butoxycarbonylaminophenyl)ethoxy)phenyl)-(s) 2-ethoxy propanoic acid
USD470527S1 (en) Camera base
JP2000204075A5 (es)
DK1387683T3 (da) Hidtil ukendte saltformer eller krystallinske former af (2R)-anti-5-3-[4-(10,11-difluormethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy quinolin
TH9154A (th) สารกำจัดตัวรังควานประเภทแกนโนฟอสฟอรัส
JPH0716705U (ja) コンパクト容器